Note 13 - Segment Information: Segment Revenue Table (Tables)

6 Months Ended

Oct. 31, 2016

Tables/Schedules

Segment Revenue Table

	Three Months Ended October 31,		Six Months Ended October 31,
	2016	2015	2016	2015
Revenues:
Chinese medicine - third party	$         706,115	$            622,793	$      1,380,122	$   1,166,966
Chinese medicine - related party	0	0	0	0
Total Chinese medicine	706,115	622,793	1,380,122	1,166,966
Stevioside - third party	2,791,223	1,677,631	4,991,995	3,036,135
Stevioside - related party	1,948,631	782,398	3,462,369	3,858,054
Total Stevioside	4,739,854	2,460,029	8,454,364	6,894,189
Total segment and consolidated revenues	$      5,445,969	$        3,082,822	$      9,834,486	$   8,061,155
Interest (expense) income:
Chinese medicine	$                    20	$                      67	$                    73	$               136
Stevioside	(88,584)	(86,124)	(169,971)	(164,549)
Total segment and consolidated interest expense	$          (88,564)	$            (86,057)	$        (169,898)	$     (164,413)
Depreciation and amortization:
Chinese medicine	$            72,856	$              60,548	$         148,049	$       152,587
Stevioside	357,468	367,791	700,999	758,021
Total segment and consolidated depreciation and amortization	$         430,324	$            428,339	$         849,048	$       910,608
Income (loss) before income taxes:
Chinese medicine	$        (191,545)	$              15,587	$        (149,896)	$          (8,606)
Stevioside	(368,871)	(306,835	(827,670)	(332,882)
Corporate and other	(350,997)	(108,918	(767,014)	(292,487)
Total consolidated (loss) income before income taxes	$        (911,413)	$          (400,166	$    (1,744,580)	$     (633,975)